Significantly superior response in the right ovary compared with the left ovary after stimulation with follicle-stimulating hormone in a pituitary down-regulation regimen.
OBJECTIVE
To compare the differences between the right and left ovarian responses in patients undergoing standard in vitro fertilization (IVF) treatment.


METHODS
Prospective, observational study.


METHODS
A university hospital in Taiwan.


METHODS
Seven hundred eighty-nine consecutive patients undergoing IVF or intracytoplasmic sperm injection.


METHODS
None.


METHODS
The number of oocytes retrieved, fertilization rates, number of grade 1 zygotes and number of embryos produced, embryo arrest-free rate, and mean number of top-quality embryos on the day of transfer.


RESULTS
The number of follicles > or = 16 mm in diameter on day 2.5 versus 2.2 of human chorionic gonadotropin (hCG) administration, the number of follicles > or = 10 mm in diameter on hCG day 6.5 versus 6.1, the number of oocytes (3.6 vs. 3.0), the percentage fertilization (79.9 vs. 74.6%), and the mean number of mature oocytes and grade 1 zygotes (2.3 vs. 1.8 and 1.79 vs. 0.93, respectively), and the mean available number of top-quality embryos on transfer day 1.39 versus 0.73 were all statistically significantly greater in the right compared with the left ovary; however, the pregnancy and implantation rates were similar.


CONCLUSIONS
There are statistically significant differences between the right and left ovarian responses in IVF patients with healthy ovaries, and the right ovarian responses are superior to the left ovarian responses.
Lan
Kuo-Chung
KC
Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University College of Medicine, Niaosung Hsiang, Kaohsiung, Taiwan. blue@adm.cgmh.org.tw
Huang
Fu-Jen
FJ
Lin
Yi-Chi
YC
Kung
Fu-Tsai
FT
Lan
Ting-Hsun
TH
Chang
Shiuh Young
SY
D000328:Adult; D002478:Cells, Cultured; D015536:Down-Regulation / Q000187:drug effects; D004338:Drug Combinations; D046149:Embryo Culture Techniques; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage; D005307:Fertilization in Vitro / Q000379:methods; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage*; D007839:Functional Laterality / Q000187:drug effects / Q000502:physiology*; D006727:Hormone Antagonists / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010053:Ovary / Q000187:drug effects* / Q000502:physiology*; D010062:Ovulation Induction / Q000379:methods*; D010902:Pituitary Gland / Q000187:drug effects* / Q000502:physiology; D010907:Pituitary Hormones / Q000037:antagonists & inhibitors; D011247:Pregnancy; D055815:Young Adult
D004338:Drug Combinations; D005300:Fertility Agents, Female; D006727:Hormone Antagonists; D010907:Pituitary Hormones; D005640:Follicle Stimulating Hormone